Similar immunogenicity of measles–mumps–rubella (MMR) vaccine administrated at 8 months versus 12 months age in children

He, Hanqing; Chen, Haiping; Wang, Zhifang; Li, Qian; Yan, Rui; Guo, Jìng; Zhou, Yang; Pan, Jinren; Xie, Shuyun

doi:10.1016/j.vaccine.2014.04.044

Cited by 25 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Half of the 8 RCT reporting immunogenicity had a low risk of bias overall [8,[68][69][70] while 4 presented a moderate risk of bias [71][72][73][74]. In quasi-experimental studies, 19 (32%) were considered at low, 26 (44%) at moderate, and 14 (24%) at high risk of bias overall (Additional file 4).…”

Section: Risk Of Bias Within Studiesmentioning

confidence: 99%

Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: The objectives of this review were to evaluate the effect of age at administration of the first dose of a measles-containing vaccine (MCV1) on protection against measles and on antibody response after one-and twodose measles vaccinations. Methods: We conducted a systematic review of the PubMed/MEDLINE, Embase, Web of Science and Cochrane databases (1964-2017) to identify observational studies estimating vaccine effectiveness and/or measles attack rates by age at first vaccination as well as experimental studies comparing seroconversion by age at first vaccination. Random effect models were used to pool measles risk ratios (RR), measles odds ratios (OR) and seroconversion RR of MCV1 administered at < 9, 9-11 or ≥ 15 months compared with 12 or 12-14 months of age. Results: We included 41 and 67 studies in the measles protection and immunogenicity analyses. Older age at MCV1, from 6 to ≥15 months, improved antibody response and measles protection among one-dose recipients. Pooled measles RR ranged from 3.56 (95%CI: 1.28, 9.88) for MCV1 at < 9 months to 0.48 (95%CI: 0.36, 0.63) for MCV1 at ≥15 months, both compared to 12-14 months. Pooled seroconversion RR ranged from 0.93 (95%CI: 0.90, 0.96) for MCV1 at 9-11 months to 1.03 (95%CI: 1.00, 1.06) for MCV1 at ≥15 months, both compared to 12 months. After a second dose, serological studies reported high seropositivity regardless of age at administration of MCV1 while epidemiological data based on few studies suggested lower protection with earlier age at MCV1. Conclusions: Earlier age at MCV1 decreases measles protection and immunogenicity after one dose and might still have an impact on vaccine failures after two doses of measles vaccine. While two-dose vaccination coverage is most critical to interrupt measles transmission, older age at first vaccination may be necessary to keep the high level of population immunity needed to maintain it.

show abstract

Section: Risk Of Bias Within Studiesmentioning

confidence: 99%

Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…There were five measles [6,12,13,19,20] and 10 rubella studies [6,12,14,19,25,43,44,63,74,87] in category 2. Each study reported testing specimens obtained from individuals having a range of ages, from infants to adulthood, and compared the seroprevalence in each age group.…”

mentioning

confidence: 99%

A 16-year review of seroprevalence studies on measles and rubella

Dimech¹,

Mulders

2016

Vaccine

View full text Add to dashboard Cite

“…Early literature on measles vaccine effectiveness showed that vaccine efficacy was lower at younger ages due to the presence of maternal antibodies; a review of 70 studies showed vaccine efficacy of 84.0% at 9 to 11 months of age and 92.5% at 12 months of age or older [30]. A more recent study found no statistical difference in the safety or immunological results of measles-mumps-rubella vaccine administered at 8 months versus 12 months [31]. Because antibody load in the mother is itself determined by the nature of the infection, with vaccination resulting in fewer antibodies produced relative to natural infection, it may be that in more recent years characterized by decreases in measles cases, fewer mothers having a history of measles disease.…”

Section: Discussionmentioning

confidence: 99%

A population profile of measles susceptibility in Tianjin, China

Boulton

Wang

Zhang

et al. 2016

Vaccine

View full text Add to dashboard Cite

Background Measles is a highly infectious illness requiring herd immunity of 95% to interrupt transmission. Measles is targeted for elimination in China, which has not reached elimination goals despite high vaccination coverage. We developed a population profile of measles immunity among residents aged 0 through 49 years in Tianjin, China. Methods Participants were either from community population registers or community immunization records. Measles IgG antibody status was assessed using dried blood spots. We examined the association between measles IgG antibody status and independent variables including urbanicity, sex, vaccination, measles history, and age. Results 2,818 people were enrolled. The proportion measles IgG negative increased from 50.7% for infants aged 1 month to 98.3% for those aged 7 months. After 8 months, the age of vaccination eligibility, the proportion of infants and children measles IgG negative decreased. Overall, 7.8% of participants 9 months of age or older lacked measles immunity including over 10% of those 20–39 years. Age and vaccination status were significantly associated with measles IgG status in the multivariable model. The odds of positive IgG status were 0.337 times as high for unvaccinated compared to vaccinated (95% CI: 0.217, 0.524). Conclusions The proportion of persons in Tianjin, China immune to measles was lower than herd immunity threshold with less than 90% of people aged 20–39 years demonstrating protection. Immunization programs in Tianjin have been successful in vaccinating younger age groups although high immunization coverage in infants and children alone won’t provide protective herd immunity, given the large proportion of non-immune adults.

show abstract

Similar immunogenicity of measles–mumps–rubella (MMR) vaccine administrated at 8 months versus 12 months age in children

Cited by 25 publications

References 23 publications

Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis

Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis

A 16-year review of seroprevalence studies on measles and rubella

A population profile of measles susceptibility in Tianjin, China

Contact Info

Product

Resources

About